Sunday, June 26, 2022

Deciphera Pharmaceuticals Inc. [DCPH] EVP & Chief Medical Officer makes an insider purchase of 1,768 shares worth 19006.0.

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Deciphera Pharmaceuticals Inc. shares valued at $19,006 were sold by Sherman Matthew L on Jun 16. At $10.75 per share, Sherman Matthew L sold 1,768 shares. The insider’s holdings dropped to 76,884 shares worth approximately $1.07 million following the completion of this transaction.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Also, Martin Daniel C. sold 1,311 shares, netting a total of over 14,093 in proceeds. Following the sale of shares at $10.75 each, the insider now holds 49,521 shares.

Before that, Pitman Jama had sold 1,298 shares from its account. In a trade valued at $13,954, the insider traded Deciphera Pharmaceuticals Inc. shares for $10.75 each. Upon closing the transaction, the insider’s holdings decreased to 1,298 shares, worth approximately $0.51 million.

As published in a research note from Barclays on February 28, 2022, Deciphera Pharmaceuticals Inc. [DCPH] has been rated down from an Equal weight to an Underweight and the price target has been revised to $6 from $11. This represents a -133.0% premium over Thursday’s closing price. Analysts at Stifel downgraded the stock from ‘”a Buy”‘ to ‘”a Hold”‘ outlook in a report released in early November. As of November 08, 2021, Canaccord Genuity has decreased its “Buy” rating to a “Hold” for DCPH. Earlier on November 08, 2021, Barclays downgraded its rating. Their new recommendation was “an Equal weight” for DCPH stock which previously was a “an Overweight”.

Analyzing DCPH’s Price Performance

On Thursday, Deciphera Pharmaceuticals Inc. [NASDAQ: DCPH] rose 6.47% to $13.98. The stock’s lowest price that day was $13.04, but it reached a high of $13.995 in the same session. During the last five days, there has been a surge of approximately 20.31%. Over the course of the year, Deciphera Pharmaceuticals Inc. shares have jumped approximately 43.09%. Shares of the company reached a 52-week high of $13.99 on 06/23/22 and a 52-week low of $6.51 on 03/08/22. A 50-day SMA is recorded $10.92, while a 200-day SMA reached $9.24. Nevertheless, trading volume fell to 1.05 million shares from 1.21 million shares the previous day.

Support And Resistance Levels for Deciphera Pharmaceuticals Inc. (DCPH)

According to the 24-hour chart, there is a support level at 13.35, which, if violated, would cause prices to drop to 12.72. In the upper region, resistance lies at 14.30. The next price resistance is at 14.63. RSI (Relative Strength Index) is 66.84 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 1.39, which suggests the price will increase in the coming days. Percent R is at 0.39%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.

Is Deciphera Pharmaceuticals Inc. subject to short interest?

Stocks of Deciphera Pharmaceuticals Inc. saw a sharp steep in short interest on May 30, 2022 dropping by 70000.0 shares to 6.71 million. Data from Yahoo Finance shows that the short interest on Apr 28, 2022 was 6.78 million shares. A decline of -1.04% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 5.4 of the overall float, the days-to-cover ratio (short ratio) decline to 5.4.

Which companies own the most shares of Deciphera Pharmaceuticals Inc. (DCPH)?

According to Armistice Capital LLC filings, the company currently owns 5,836,000 shares, which is about 8.81% of the total DCPH shares outstanding. The investor’s shares have appreciated by 2,405,846 from its previous 13-F filing of 3430154.0 shares. With the completion of the sale transaction, SSgA Funds Management, Inc.’s stake is now worth $62,208,267. Deerfield Management Company LP reduced a 0.00% interest valued at $60.49 million while The Vanguard Group, Inc. purchased a 134,220 stake. A total of 371,325 shares of Deciphera Pharmaceuticals Inc. were bought by BlackRock Fund Advisors during the quarter, and 1,090,368 were bought by Federated MDTA LLC. In its current portfolio, Redmile Group LLC holds 1,430,917 shares valued at $15.51 million.

In terms of Deciphera Pharmaceuticals Inc. share price expectations, FactSet research, analysts set an average price target of $10.78 in the next 12 months, down nearly -16.22% from the previous closing price of $13.13. Analysts anticipate Deciphera Pharmaceuticals Inc. stock to reach $15.00 by 2022, with the lowest price target being $6.00. In spite of this, 11 analysts ranked Deciphera Pharmaceuticals Inc. stock as a Hold at the end of 2022. On November 05, 2021, Truist assigned a price target of “a Hold” to the stock and downgraded coverage with a $10.

Latest news

Related news


Please enter your comment!
Please enter your name here




Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam